1.
Network meta-analysis of platelet-rich fibrin in periodontal intrabony defects
Ye L, Mashrah MA, Ge L, Fang Y, Guo X, Ge Q, Wang L
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2023
Abstract
OBJECTIVES To evaluate the effect of platelet-rich fibrin alone or in combination with different biomaterials for the treatment of periodontal intra-bony defect. METHODS Up to April 2022, Cochrane library, Medline, EMBASE, and Web of Science databases were searched for randomized clinical trials. The outcomes of interest were probing pocket depth reduction, clinical attachment level gain, bone gain, and bone defect depth reduction. Bayesian network meta-analysis with 95% credible intervals was calculated. RESULTS Thirty-eight studies with 1,157 participants were included. Platelet-rich fibrin alone or platelet-rich fibrin +biomaterials showed a statistically significant difference when compared with open flap debridement (P<0.05, low to high certainty evidence). Neither biomaterials alone nor platelet-rich fibrin +biomaterials showed a statistically insignificant difference when compared to platelet-rich fibrin alone (P>0.05, very low to high certainty evidence). Platelet-rich fibrin +biomaterials showed insignificant differences as compared to biomaterials alone (P>0.05, very low to high certainty evidence). Allograft +collagen membrane ranked the best in probing pocket depth reduction while platelet-rich fibrin +hydroxyapatite ranked the best in bone gain. CONCLUSION It seems that 1) Platelet-rich fibrin with/without biomaterials were more effective than open flap debridement. 2) Platelet-rich fibrin alone provides a comparable effect to biomaterials alone and platelet-rich fibrin +biomaterials. 3)Platelet-rich fibrin +biomaterials provide a comparable effect to biomaterials alone. Although allograft +collagen membrane and platelet-rich fibrin +hydroxyapatite ranked the best in terms of probing pocket depth reduction and bone gain respectively, the difference between different regenerative therapies remains insignificant, and therefore, further studies are still needed to confirm these results.
3.
The Effect of Perioperative Blood Transfusion on Long-Term Survival Outcomes After Surgery for Pancreatic Ductal Adenocarcinoma: A Systematic Review
Ye L, Livingston EH, Myers B, Hines OJ
Pancreas. 2021;50(5):648-656
-
-
Free full text
-
Abstract
OBJECTIVE To evaluate survival outcomes associated with perioperative allogeneic red blood cell transfusion (RBCT) in patients with pancreatic ductal adenocarcinoma undergoing surgery. METHODS PubMed, Embase, Cochrane, and Web of Science Core Collection were queried for English-language articles until May 28, 2020. Studies evaluating long-term outcomes of RBCT compared with no transfusion in adults with pancreatic ductal adenocarcinoma undergoing pancreatectomy were included. E-value sensitivity analysis assessed the potential for unmeasured confounders to overcome these findings. RESULTS Of 4379 citations, 5 retrospective cohort studies were included. Three studies reported shorter recurrence-free survival by 1 to 5 months with RBCT. Two studies found shorter disease-specific survival by 5 to 13 months with RBCT. Overall survival was reduced by 5 to 7 months with RBCT in 3 studies. All multivariable findings associated with RBCT could be readily overcome unmeasured confounding on sensitivity analysis. Confounding in baseline characteristics resulted in high risk of bias. CONCLUSIONS Imprecision, unmeasured confounding, small effect sizes, and overall low quality of the available literature result in uncertainty regarding the effect of transfusion on recurrence-free survival, disease-specific survival, and overall survival in patients undergoing surgery for pancreatic cancer. Randomized trials are needed to determine if there is a causal relationship between transfusion and survival after pancreatic resection.
4.
Prognosis of COVID-19 in patients with vein thrombosis: a systematic review and meta-analysis
Wang C, Zhang H, Zhou M, Cheng Y, Ye L, Chen J, Wang M, Feng Z
European Review for Medical and Pharmacological Sciences. 2020;24(19):10279-10285
Abstract
OBJECTIVE SARS-CoV-2 is currently affecting millions of humans worldwide, thus contributing to the COVID-19 pandemic. Thromboembolic events have a higher incidence among patients with COVID-19, but there are few reports on the relationship between the prognosis of COVID-19 patients and thromboembolic events. The objectives of this meta-analysis were to explore the relationship between the prognosis of COVID-19 patients and thromboembolic events. MATERIALS AND METHODS Medline (PubMed), the Web of Science, Embase, and the Cochrane Library were searched for case-control studies that included data on vein thrombosis in patients with COVID-19 and were published in English, between January 1 and July 25, 2020. According to the inclusion and exclusion criteria, the included data were confirmed, the prognoses of patients with and without concurrent thromboembolic events were compared, and the odds ratio (OR) was used as the effect size. RESULTS Eighteen studies (2,030 patients) were included. Thromboembolic events complicated a total of 609 COVID-19 patients. The combined OR of the mortality of COVID-19 patients with thromboembolic events was 1.93 (95% CI: 1.13-3.27), that of ICU treatment rate was 2.63 (95% CI: 1.49-4.67), and that of treatment with invasive mechanical ventilation was 3.14 (95% CI: 1.97-5.02). CONCLUSIONS As compared with COVID-19 patients with and without thromboembolism, the mortality, ICU treatment rate, and invasive mechanical ventilation treatment rate of COVID-19 patients with thromboembolism were found to be increased significantly, and the prognosis was worse.
5.
The adjunctive use of platelet concentrates in the therapy of gingival recessions: a systematic review and meta-analysis
Luo HY, Li RM, Wang CL, Peng L, Ye L
Journal of Oral Rehabilitation. 2015;42((7)):552-61.
Abstract
This systematic review aims to evaluate the adjunctive efficacy of platelet concentrates in surgical treatment of gingival recessions. The MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials were searched for entries up to January 2014. Only clinical randomised controlled trials (RCTs) with a follow-up >3 months that evaluated recession areas (Miller Class I or II) were included. Outcome variables include changes of recession depth (RD), keratinised tissue width (KTW), clinical attachment level (CAL) and wound healing index. Data were adjusted for a meta-analysis. Nine researches were included in meta-analysis. With the adjunctive use of platelet concentrates, there was statistically significant reduction in RD and KTW improvement while no significant effect was found in CAL. The adjunctive use of platelet concentrates also showed better healing in gingival recessions. Platelet concentrates might exert a positive effect on treatment of gingival recessions. It could accelerate early wound healing and reduce post-surgery complications in recession defects. However, more high-quality, long follow-up and large-scale RCTs are still needed in future. Copyright © 2015 John Wiley & Sons Ltd.